跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/2023-503421-19-00
2023-503421-19-00招募中3 期

C5701003 - An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer

Seagen Inc.57 个研究点 分布在 8 个国家目标入组 703 人开始时间: 2023年11月10日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
3 期
状态
招募中
发起方
Seagen Inc.
入组人数
703
试验地点
57
主要终点
1. PFS per RECIST v1.1 by BICR.
研究概览入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

  1. To compare PFS between the experimental arm (enfortumab vedotin +pembrolizumab [Arm A] and the control arm (gemcitabine + cisplatin or carboplatin [Arm B]) by blinded independent central review (BICR).
  2. To compare overall survival (OS) between the experimental arm (Arm A) and the control arm (Arm B).

入排标准

年龄范围
18 years 至 65+ years（65+ Years, 18-64 Years）
接受健康志愿者
是

入选标准

  • •Subjects must have histologically documented, unresectable locally advanced or metastatic urothelial carcinoma (ie, cancer of the bladder, renal pelvis, ureter, or urethra). Subjects with squamous or sarcomatoid differentiation or mixed cell types are eligible.
  • •4a)ii. ECOG or WHO performance status of 2 (refer to Inclusion 7 for additional criteria for ECOG 2 subjects);
  • •4a)iii. NCI CTCAE Grade ≥2 audiometric hearing loss;
  • •4a)iv. NYHA Class III heart failure.
  • •Subjects must be age 18 years or older.
  • •Archival tumor tissue comprising muscle-invasive urothelial carcinoma, or a biopsy of metastatic urothelial carcinoma must be provided for PD-L1 testing prior to randomization. If adequate archival tumor sample is not available, or evaluable, a new biopsy sample may be performed.
  • •Subjects must have an ECOG Performance Status score of 0, 1, or 2:
  • •7a. Subjects with ECOG performance status of 2 must additionally meet the following criteria:
  • •7a)i. Hemoglobin ≥10 g/dL;
  • •7a)ii. GFR ≥50 mL/min;
  • •7a)iii. May not have NYHA Class III heart failure.
  • •2.Subjects must have measurable disease by investigator assessment according to RECIST v1.1.:
  • •Subjects must have adequate hematologic and organ function as defined by the baseline laboratory values in Table 3 (see protocol).
  • •Female subjects of childbearing potential must meet the following conditions:
  • •9a. Agree not to try to become pregnant during the study and for at least 6 months after the final dose of study drug.
  • •9b. Must have a negative urine or serum pregnancy test (minimum sensitivity of 25 mIU/mL or equivalent units of beta human chorionic gonadotropin [β-hCG]) within 1 day prior to administration of study drug. Female subjects with false positive results and documented verification of negative pregnancy status are eligible for participation.
  • •9c. If heterosexually active, must consistently use highly effective methods of birth control, with a failure rate of less than 1% starting at screening, throughout the study period, and for at least 6 months after the final dose of study drug.
  • •9d. Female subjects must agree not to breastfeed or donate ova starting at screening and throughout the study period, and for at least 6 months after the final dose of study drug.
  • •Male subjects who can father children, must meet the following conditions:
  • •10a. Must not donate sperm starting at screening and throughout the study period, and for at least 6 months after the final dose of study drug (see protocol);
  • •10b. Must consistently use highly effective methods of birth control, with a failure rate of less than 1% starting at screening and continue throughout study period and for at least 6 months after the final dose of study drug;
  • •10c. Male subjects with a pregnant or breastfeeding partner(s) must consistently use one of 2 contraception options for preventing secondary exposure to seminal fluid for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for at least 6 months after the final dose of study drug.
  • •2a. Subjects with prior definitive radiation therapy must have measurable disease per RECIST v1.1 that is outside the radiation field or has demonstrated unequivocal progression since completion of radiation therapy.
  • •Subjects must provide written informed consent.
  • •Subjects must not have received prior systemic therapy for locally advanced or metastatic urothelial carcinoma with the following exceptions:
  • •3a. Subjects that received neoadjuvant chemotherapy with recurrence >12 months from completion of therapy are permitted;
  • •3b. Subjects that received adjuvant chemotherapy following cystectomy with recurrence >12 months from completion of therapy are permitted;
  • •Subjects must be considered eligible to receive cisplatin- or carboplatin-containing chemotherapy, in the investigator’s judgment.
  • •4a. Subjects will be considered cisplatin-ineligible, and will receive carboplatin, if they meet at least one of the following criteria:
  • •4a)i. GFR <60 mL/min but ≥30 mL/min (measured by the Cockcroft-Gault formula, Modification of Diet in Renal Disease [MDRD] or 24-hour urine): Subjects with a GFR ≥50 mL/min and no other cisplatin ineligibility criteria may be considered cisplatin-eligible based on the investigator’s clinical judgment;

排除标准

  • •Subjects who have previously received enfortumab vedotin or other MMAE-based ADCs.
  • •Subjects with known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin; any pembrolizumab excipient contained in the drug formulations of pembrolizumab; the platinum agent selected by the investigator for study treatment; the gemcitabine.
  • •Subjects with active keratitis or corneal ulcerations. Subjects with superficial punctate keratitis are allowed if the disorder is being adequately treated in the opinion of the investigator
  • •Subjects who have received prior treatment with a PD-(L)-1 inhibitor for any malignancy, including earlier stage UC, defined as a PD-1 inhibitor or PD-L1 inhibitor (see protocol).
  • •History of autoimmune disease that has required systemic treatment in the past 2 years (see protocol):
  • •Subjects who have previously received any prior treatment with an agent directed to another stimulatory or co inhibitory T-cell receptor (see protocol).
  • •Subjects who have received anti-cancer treatment with chemotherapy, biologics, or investigational agents not otherwise prohibited by exclusion criterion 1-3 that is not completed 4 weeks prior to first dose of study treatment (see protocol).
  • •Subjects with uncontrolled diabetes (see protocol).
  • •Subjects with an estimated life expectancy <12 weeks.
  • •Subjects with ongoing sensory or motor neuropathy Grade 2 or higher.
  • •Subjects with active CNS metastases. Subjects with treated CNS metastases are permitted on study if all of the following are true:
  • •Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted.
  • •Subjects with ongoing clinically significant toxicity associated with prior treatment (including radiotherapy or surgery) that has not resolved to ≤ Grade 1 or returned to baseline.
  • •8a) CNS metastases have been clinically stable for at least 4 weeks prior to screening and baseline scans show no evidence of new or enlarged metastasis;
  • •8b) the subject is on a stable dose of ≤10 mg/day of prednisone or equivalent for at least 2 weeks (if requiring steroid treatment);
  • •8c) subject does not have leptomeningeal disease.
  • •20a. Replacement therapy (eg, thyroxine, insulin, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
  • •20b. Brief (<7 days) use of systemic corticosteroids is allowed when use is considered standard of care.
  • •20c. Subjects with vitiligo, psoriasis, type 1 diabetes mellitus, hypothyroidism, or resolved childhood asthma/atopy will not be excluded.
  • •20d. Subjects requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections will not be excluded.
  • •20e. Subjects with hypothyroidism that is stable with hormone replacement or Sjögren's syndrome will not be excluded.
  • •Subjects with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  • •Subjects who have known active hepatitis B (defined as HBsAg reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] detected) infection, testing for hepatitis B and hepatitis C is required if mandated by country health authority. Subjects who have been curatively treated for hepatitis C infection are permitted if they have documented sustained virologic response of 12 weeks.
  • •Subjects who have received a prior allogeneic stem cell or solid organ transplant.
  • •Subjects who have received a live attenuated vaccine within 30 days prior to randomization (see protocol).
  • •Subjects with active tuberculosis.
  • •Subjects with another underlying medical condition that, in the opinion of the investigator, would impair the ability of the subject to receive or tolerate the planned treatment and follow-up; any known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study.
  • •Has a known history of human immunodeficiency virus (HIV) infection. Testing is not required unless mandated by the local health authority.
  • •Subjects with conditions requiring high doses of steroids (>10 mg/day of prednisone or equivalent) or other immunosuppressive medications are excluded. Inhaled or topical steroids are permitted in the absence of active autoimmune disease. Physiologic replacement doses of corticosteroids are permitted for subjects with adrenal insufficiency.
  • •Subjects with a history of another invasive malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with nonmelanoma skin cancer or carcinoma in situ of any type (if complete resection was performed) are allowed (for details eligible exceptions see protocol).
  • •Subjects with a documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with NYHA Class IV within 6 months prior to randomization.
  • •Subjects who have received radiotherapy within 2 weeks prior to randomization. Subject must have recovered adequately from the toxicity from the intervention prior to starting study treatment.
  • •Subjects who have received major surgery within 4 weeks prior to randomization. Subject must have recovered adequately from complications from the intervention prior to starting study treatment.

结局指标

主要结局

1. PFS per RECIST v1.1 by BICR.

1. PFS per RECIST v1.1 by BICR.

2. OS.

2. OS.

次要结局

  • 4. PFS per RECIST v1.1 by investigator assessment.
  • 1. ORR per RECIST v1.1 by BICR.
  • 2. TTPP.
  • 3. Mean change from baseline in worst pain at Week 26.
  • 5. ORR per RECIST v1.1 by investigator assessment.
  • 6. DOR per RECIST v1.1 by BICR.
  • 7. DOR per RECIST v1.1 by investigator assessment.
  • 8. DCR per RECIST v1.1 by BICR.
  • 9. DCR per RECIST v1.1 by investigator assessment.
  • 10. Mean scores and change from baseline of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30), and EuroQOL 5-dimensions (EQ-5D-5L), visual analogue scale (VAS), and utility scores.
  • 11. Type, incidence, relatedness, severity and seriousness of AEs.
  • 12. Type, incidence and severity of laboratory abnormalities.
  • 13. Treatment discontinuation rate due to AEs.

研究者

发起方
Seagen Inc.
申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Seagen Trial Information Support

Scientific

Seagen Inc.

研究点 (57)

Loading locations...

相似试验

招募中
3 期
Phase 3 Study of V940 and Pembrolizumab in Resected MelanomaMelanoma
2023-503652-27-00Merck Sharp & Dohme LLC596
招募中
2 期
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy (PIERCE)
2024-515646-16-00AGO Research GmbH42
招募中
3 期
A Phase 3 randomized clinical Study of Pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen as first line treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2024-512015-47-00Incyte Corp.42
招募中
3 期
A study of MK7684A versus Pembrolizumab in PD-L1 Positive Metastatic NSCLC (KEYVIBE-003)
2023-505362-28-00Merck Sharp & Dohme LLC156
尚未招募
3 期
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
NCT07277842Sun Yat-sen University382